RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED, DOSE-ESCALATION TRIAL OF A HUMANIZED RESPIRATORY SYNCYTIAL VIRUS (RSV) MONOCLONAL ANTIBODY (MEDI-493) IN HIGH RISK INFANTS. • 768
Autor: | T. Rhodes, E. Connor, Leonard E. Weisman, K. N. Siva Subramanian |
---|---|
Rok vydání: | 1997 |
Předmět: | |
Zdroj: | Pediatric Research. 41:130-130 |
ISSN: | 1530-0447 0031-3998 |
DOI: | 10.1203/00006450-199704001-00788 |
Popis: | AIM: MEDI-493 is directed against the F protein of RSVand is broadly reactive against RSV in vitro. Serum levels of 25-30 ug/ml result in a 2-log reduction of RSV in cotton rats. This study describes the safety, immunogenicity and pharmacokinetics of MEDI-493 in high risk children. |
Databáze: | OpenAIRE |
Externí odkaz: |